Tag Archives: biotechnology law

Infringement by Unobvious Changes – A Look (Way) Back

As a much younger attorney, I gave a presentation at the 1990 AIPLA Annual Meeting:  “A Review of Recent Federal Circuit Decisions Relating to Infringement” (AIPLA Selected Legal Papers, 9, 3 (July 1991)), in which I wrestled with the question … Continue reading

Posted in Doctrine of Equivalents, Infringement | Tagged , , , , , , , , , , , , | Leave a comment

Obviousness = Equivalence? Saint-Gobain v. Siemens

Saint-Gobain Ceramics (“S-G”) has asked the Supreme Court to review the Fed. Cir. panel below, 647 F.3d 1373 (Fed. Cir. 2011) in which the panel decision refused to reverse a district court decision that instructed the jury that it could … Continue reading

Posted in Doctrine of Equivalents | Tagged , , , , , , , , , , , , , , | 1 Comment

Cordis v. BSC – Therasense at Work

Last week the Fed. Cir. affirmed the district court’s finding of no inequitable conduct, due to the failure of the applicant or his attorney to cite a relevant prior art reference in a parent application that yielded the two patents-in-suit. … Continue reading

Posted in Inequitable Conduct/Rule 56 | Tagged , , , , , , , , , | Leave a comment

Myriad Petition For Rehearing Denied

On September 13, 2011, the Fed. Cir. panel in AMP v. Myriad denied AMP’s (read ACLU’s) petition for rehearing by the panel. (A copy of the petition can be found at the end of this post.) In challenging the holding … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | Leave a comment